Dr. Choi on Considering Factors for RT in Prostate Cancer

Video

In Partnership With:

Seungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the considering factors for patients to receive radiation therapy (RT) for their prostate cancer.

Seungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical medical director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the considering factors for patients to receive radiation therapy (RT) for their prostate cancer.

One of the challenges with choosing treatment is that are numerous options available, Choi explains. However, for most patients, both surgery and RT are good options with a very high chance for cure and low risk for side effects. Nevertheless, there are some patients who are more likely to benefit from RT, which are those who have comorbidities, such as heart disease. Other patients who might benefit better are those with very aggressive disease who might undergo RT anyway even if they had surgery. It is controversial whether RT by itself is less effective than RT plus surgery he adds.

There are some side effects that some patients want to avoid when choosing between treatments. Urinary incontinence is a risk factor with surgery and is not as common with RT.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD